Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |15 October 2002

Ximelagatran versus Warfarin To Prevent Blood Clots after Knee Replacement Surgery

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • The summary below is from the full report titled “Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty. A Randomized, Double-Blind Trial.” It is in the 15 October 2002 issue of Annals of Internal Medicine (volume 137, pages 648-655). The authors are CW Francis, BL Davidson, SD Berkowitz, PA Lotke, JS Ginsberg, JR Lieberman, AK Webster, JP Whipple, GR Peters, and CW Colwell Jr.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Deep venous thrombosis (DVT), a condition in which blood clots form in leg veins and cause pain and swelling, is a common complication of knee replacement surgery. Pieces of these clots can break off and travel to the lungs, causing a serious and potentially deadly condition called pulmonary embolism. To prevent DVT, doctors prescribe blood thinners around the time of knee replacement surgery. Warfarin is a common blood thinner used for this purpose. Unfortunately, up to almost half of patients still develop DVT after knee replacement surgery even if they take warfarin. In addition, warfarin requires frequent blood tests and dose changes to make sure that patients are getting an appropriate amount of the drug. Ximelagatran is a newer blood thinner that has shown some promise in preventing DVT after hip and knee replacement surgery. An advantage of ximelagatran is that it does not require blood tests or dose changes.

Why did the researchers do this particular study?

To compare warfarin and ximelagatran in the prevention of DVT after knee replacement surgery.

Who was studied?

680 patients who had total knee replacement surgery at one of 74 North American hospitals.

How was the study done?

The researchers randomly assigned patients to get 1) ximelagatran twice a day beginning on the morning of the day of surgery or 2) warfarin once daily starting the evening of the day of surgery. They followed patients with tests to look for DVT, pulmonary embolism, and bleeding complications.

What did the researchers find?

Deep venous thrombosis occurred at similar rates in both groups. Bleeding complications were also similar in both groups.

What were the limitations of the study?

This study had limited ability to compare the side effects of ximelagatran and warfarin.

What are the implications of the study?

Ximelagatran seems to be a reasonable option for preventing DVT after knee replacement surgery.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Ximelagatran versus Warfarin To Prevent Blood Clots after Knee Replacement Surgery. Ann Intern Med. 2002;137:I–38. doi: https://doi.org/10.7326/0003-4819-137-8-200210150-00003

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2002;137(8):I-38.

DOI: 10.7326/0003-4819-137-8-200210150-00003

©
2002 American College of Physicians
0 Citations

See Also

Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty: A Randomized, Double-Blind Trial
View MoreView Less

Related Articles

Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty: A Randomized, Double-Blind Trial
Annals of Internal Medicine; 137 (8): 648-655
Use of a New Form of the Blood Thinner Heparin Outside the Hospital To Prevent Blood Clots after Hip or Knee Replacement
Annals of Internal Medicine; 132 (11): 853
Prevention of Venous Thromboembolism after Knee Arthroplasty: A Randomized, Double-Blind Trial Comparing Enoxaparin with Warfarin
Annals of Internal Medicine; 124 (7): 619-626
Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review
Annals of Internal Medicine; 169 (11): 774-787
View MoreView Less

Journal Club

Review: DOACs reduce intracranial hemorrhage more than warfarin in AF with CKD
Annals of Internal Medicine; 168 (4): JC18
Guideline: Recommendations for THA or TKA perioperative antirheumatic drugs in patients with rheumatic diseases
Annals of Internal Medicine; 167 (10): JC50
Resuming warfarin after intracranial hemorrhage in patients with AF was linked to reduced mortality
Annals of Internal Medicine; 166 (12): JC70
Review: In AF, direct oral anticoagulants reduce all-cause and vascular mortality compared with warfarin
Annals of Internal Medicine; 166 (6): JC28
View MoreView Less

Related Topics

Venous Thromboembolism

Venous Thromboembolism.

PubMed Articles

ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial.
Atherosclerosis 2019;
Use of Direct Oral Anticoagulants in Morbidly Obese Patients.
Pharmacotherapy 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×